Comment from Philp Steelman

Summary: Philip Steelman, a patient with Microscopic Polyangiitis, urges the FDA not to withdraw approval of Tavneos. He argues that the medication has been a "miracle" for his health and that its therapeutic benefits for thousands of patients outweigh the risks of liver injury.